[
  {
    "DatasetID": "GBM-PRJNA482620_anti-PD-1",
    "Dataset": "PRJNA482620",
    "CancerType": "Glioblastoma",
    "Therapy": "anti-PD-1",
    "PMID": "30996326",
    "Article Title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma",
    "SampleSize": "34",
    "ResponseSampleCount": "17",
    "NonresponseSampleCount": "17",
    "PretherapySampleCount": "34",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "GBM-PRJNA482620_anti-PD-1_Female",
    "Dataset": "PRJNA482620",
    "CancerType": "Glioblastoma",
    "Therapy": "anti-PD-1",
    "PMID": "30996326",
    "Article Title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma",
    "SampleSize": "15",
    "ResponseSampleCount": "6",
    "NonresponseSampleCount": "9",
    "PretherapySampleCount": "15",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "GBM-PRJNA482620_anti-PD-1_Male",
    "Dataset": "PRJNA482620",
    "CancerType": "Glioblastoma",
    "Therapy": "anti-PD-1",
    "PMID": "30996326",
    "Article Title": "Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma",
    "SampleSize": "19",
    "ResponseSampleCount": "11",
    "NonresponseSampleCount": "8",
    "PretherapySampleCount": "19",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "HNSC-GSE93157_anti-PD-1",
    "Dataset": "GSE93157",
    "CancerType": "Squamous head and neck",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "5",
    "ResponseSampleCount": "2",
    "NonresponseSampleCount": "3",
    "PretherapySampleCount": "5",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "LUSC-GSE93157_anti-PD-1",
    "Dataset": "GSE93157",
    "CancerType": "Squamous lung carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "13",
    "ResponseSampleCount": "3",
    "NonresponseSampleCount": "10",
    "PretherapySampleCount": "13",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "LUSC-GSE93157_anti-PD-1_Female",
    "Dataset": "GSE93157",
    "CancerType": "Squamous lung carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "1",
    "ResponseSampleCount": "0",
    "NonresponseSampleCount": "1",
    "PretherapySampleCount": "1",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "LUSC-GSE93157_anti-PD-1_Male",
    "Dataset": "GSE93157",
    "CancerType": "Squamous lung carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "12",
    "ResponseSampleCount": "3",
    "NonresponseSampleCount": "9",
    "PretherapySampleCount": "12",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "Melanoma-GSE100797_ACT",
    "Dataset": "GSE100797",
    "CancerType": "Melanoma",
    "Therapy": "ACT",
    "PMID": "29170503",
    "Article Title": "Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.",
    "SampleSize": "25",
    "ResponseSampleCount": "10",
    "NonresponseSampleCount": "15",
    "PretherapySampleCount": "25",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "Melanoma-GSE106128_DCs_treated",
    "Dataset": "GSE106128",
    "CancerType": "Melanoma",
    "Therapy": "Dcs_treated",
    "PMID": "29682201",
    "Article Title": "Molecular Signatures Associated with Prolonged Survival In Melanoma Patients Treated with Dendritic Cell-Based Immunotherapy (human)",
    "SampleSize": "47",
    "ResponseSampleCount": "21",
    "NonresponseSampleCount": "14",
    "PretherapySampleCount": "8",
    "PosttherapySampleCount": "39"
  },
  {
    "DatasetID": "Melanoma-GSE106128_DCs_treated_Female",
    "Dataset": "GSE106128",
    "CancerType": "Melanoma",
    "Therapy": "Dcs_treated",
    "PMID": "29682201",
    "Article Title": "Molecular Signatures Associated with Prolonged Survival In Melanoma Patients Treated with Dendritic Cell-Based Immunotherapy (human)",
    "SampleSize": "9",
    "ResponseSampleCount": "6",
    "NonresponseSampleCount": "3",
    "PretherapySampleCount": "2",
    "PosttherapySampleCount": "7"
  },
  {
    "DatasetID": "Melanoma-GSE106128_DCs_treated_Male",
    "Dataset": "GSE106128",
    "CancerType": "Melanoma",
    "Therapy": "Dcs_treated",
    "PMID": "29682201",
    "Article Title": "Molecular Signatures Associated with Prolonged Survival In Melanoma Patients Treated with Dendritic Cell-Based Immunotherapy (human)",
    "SampleSize": "38",
    "ResponseSampleCount": "15",
    "NonresponseSampleCount": "11",
    "PretherapySampleCount": "6",
    "PosttherapySampleCount": "32"
  },
  {
    "DatasetID": "Melanoma-GSE115821_ALL",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "ALL",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "35",
    "ResponseSampleCount": "3",
    "NonresponseSampleCount": "32",
    "PretherapySampleCount": "13",
    "PosttherapySampleCount": "22"
  },
  {
    "DatasetID": "Melanoma-GSE115821_anti-CTLA-4",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "8",
    "ResponseSampleCount": "2",
    "NonresponseSampleCount": "6",
    "PretherapySampleCount": "4",
    "PosttherapySampleCount": "4"
  },
  {
    "DatasetID": "Melanoma-GSE115821_anti-CTLA-4+anti-PD-1",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4+anti-PD-1",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "2",
    "ResponseSampleCount": "0",
    "NonresponseSampleCount": "2",
    "PretherapySampleCount": "1",
    "PosttherapySampleCount": "1"
  },
  {
    "DatasetID": "Melanoma-GSE115821_anti-CTLA-4_Female",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "2",
    "ResponseSampleCount": "0",
    "NonresponseSampleCount": "2",
    "PretherapySampleCount": "1",
    "PosttherapySampleCount": "1"
  },
  {
    "DatasetID": "Melanoma-GSE115821_anti-CTLA-4_Male",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "6",
    "ResponseSampleCount": "2",
    "NonresponseSampleCount": "4",
    "PretherapySampleCount": "3",
    "PosttherapySampleCount": "3"
  },
  {
    "DatasetID": "Melanoma-GSE115821_anti-PD-1",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "25",
    "ResponseSampleCount": "1",
    "NonresponseSampleCount": "24",
    "PretherapySampleCount": "8",
    "PosttherapySampleCount": "17"
  },
  {
    "DatasetID": "Melanoma-GSE115821_anti-PD-1_Female",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "14",
    "ResponseSampleCount": "0",
    "NonresponseSampleCount": "14",
    "PretherapySampleCount": "3",
    "PosttherapySampleCount": "11"
  },
  {
    "DatasetID": "Melanoma-GSE115821_anti-PD-1_Male",
    "Dataset": "GSE115821",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "30127394",
    "Article Title": "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma",
    "SampleSize": "11",
    "ResponseSampleCount": "1",
    "NonresponseSampleCount": "10",
    "PretherapySampleCount": "5",
    "PosttherapySampleCount": "6"
  },
  {
    "DatasetID": "Melanoma-GSE78220_anti-PD-1",
    "Dataset": "GSE78220",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "28129544",
    "Article Title": "Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma",
    "SampleSize": "28",
    "ResponseSampleCount": "15",
    "NonresponseSampleCount": "13",
    "PretherapySampleCount": "27",
    "PosttherapySampleCount": "1"
  },
  {
    "DatasetID": "Melanoma-GSE78220_anti-PD-1_Female",
    "Dataset": "GSE78220",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "28129544",
    "Article Title": "Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma",
    "SampleSize": "8",
    "ResponseSampleCount": "4",
    "NonresponseSampleCount": "4",
    "PretherapySampleCount": "8",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "Melanoma-GSE78220_anti-PD-1_Male",
    "Dataset": "GSE78220",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "28129544",
    "Article Title": "Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma",
    "SampleSize": "20",
    "ResponseSampleCount": "11",
    "NonresponseSampleCount": "9",
    "PretherapySampleCount": "19",
    "PosttherapySampleCount": "1"
  },
  {
    "DatasetID": "Melanoma-GSE91061_anti-PD-1",
    "Dataset": "GSE91061",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "29033130",
    "Article Title": "Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab",
    "SampleSize": "109",
    "ResponseSampleCount": "20",
    "NonresponseSampleCount": "78",
    "PretherapySampleCount": "51",
    "PosttherapySampleCount": "58"
  },
  {
    "DatasetID": "Melanoma-GSE93157_anti-PD-1",
    "Dataset": "GSE93157",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "25",
    "ResponseSampleCount": "9",
    "NonresponseSampleCount": "16",
    "PretherapySampleCount": "25",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "Melanoma-GSE93157_anti-PD-1_Female",
    "Dataset": "GSE93157",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "7",
    "ResponseSampleCount": "2",
    "NonresponseSampleCount": "5",
    "PretherapySampleCount": "7",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "Melanoma-GSE93157_anti-PD-1_Male",
    "Dataset": "GSE93157",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "18",
    "ResponseSampleCount": "7",
    "NonresponseSampleCount": "11",
    "PretherapySampleCount": "18",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "Melanoma-GSE96619_anti-PD-1",
    "Dataset": "GSE96619",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "28494868",
    "Article Title": "Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression",
    "SampleSize": "10",
    "ResponseSampleCount": "0",
    "NonresponseSampleCount": "0",
    "PretherapySampleCount": "5",
    "PosttherapySampleCount": "5"
  },
  {
    "DatasetID": "Melanoma-Nathanson_2017_anti-CTLA-4",
    "Dataset": "Nathanson_2017",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "27956380",
    "Article Title": "Somatic Mutations and Neoepitope Homology in\r\nMelanomas Treated with CTLA-4 Blockade",
    "SampleSize": "24",
    "ResponseSampleCount": "8",
    "NonresponseSampleCount": "16",
    "PretherapySampleCount": "9",
    "PosttherapySampleCount": "15"
  },
  {
    "DatasetID": "Melanoma-Nathanson_2017_anti-CTLA-4_Female",
    "Dataset": "Nathanson_2017",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "27956380",
    "Article Title": "Somatic Mutations and Neoepitope Homology in\r\nMelanomas Treated with CTLA-4 Blockade",
    "SampleSize": "13",
    "ResponseSampleCount": "4",
    "NonresponseSampleCount": "9",
    "PretherapySampleCount": "4",
    "PosttherapySampleCount": "9"
  },
  {
    "DatasetID": "Melanoma-Nathanson_2017_anti-CTLA-4_Male",
    "Dataset": "Nathanson_2017",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "27956380",
    "Article Title": "Somatic Mutations and Neoepitope Homology in\r\nMelanomas Treated with CTLA-4 Blockade",
    "SampleSize": "11",
    "ResponseSampleCount": "4",
    "NonresponseSampleCount": "7",
    "PretherapySampleCount": "5",
    "PosttherapySampleCount": "6"
  },
  {
    "DatasetID": "Melanoma-phs000452_anti-PD-1",
    "Dataset": "phs000452",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "26359337",
    "Article Title": "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma",
    "SampleSize": "153",
    "ResponseSampleCount": "63",
    "NonresponseSampleCount": "90",
    "PretherapySampleCount": "1",
    "PosttherapySampleCount": "152"
  },
  {
    "DatasetID": "Melanoma-phs000452_anti-PD-1_Female",
    "Dataset": "phs000452",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "26359337",
    "Article Title": "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma",
    "SampleSize": "63",
    "ResponseSampleCount": "26",
    "NonresponseSampleCount": "37",
    "PretherapySampleCount": "1",
    "PosttherapySampleCount": "62"
  },
  {
    "DatasetID": "Melanoma-phs000452_anti-PD-1_Male",
    "Dataset": "phs000452",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4",
    "PMID": "26359337",
    "Article Title": "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma",
    "SampleSize": "90",
    "ResponseSampleCount": "37",
    "NonresponseSampleCount": "53",
    "PretherapySampleCount": "0",
    "PosttherapySampleCount": "90"
  },
  {
    "DatasetID": "Melanoma-PRJEB23709_ALL",
    "Dataset": "PRJEB23709",
    "CancerType": "Melanoma",
    "Therapy": "ALL",
    "PMID": "30753825",
    "Article Title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "SampleSize": "91",
    "ResponseSampleCount": "49",
    "NonresponseSampleCount": "42",
    "PretherapySampleCount": "73",
    "PosttherapySampleCount": "18"
  },
  {
    "DatasetID": "Melanoma-PRJEB23709_anti-CTLA-4+anti-PD-1",
    "Dataset": "PRJEB23709",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4+anti-PD-1",
    "PMID": "30753825",
    "Article Title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "SampleSize": "41",
    "ResponseSampleCount": "26",
    "NonresponseSampleCount": "15",
    "PretherapySampleCount": "32",
    "PosttherapySampleCount": "9"
  },
  {
    "DatasetID": "Melanoma-PRJEB23709_anti-CTLA-4+anti-PD-1_Female",
    "Dataset": "PRJEB23709",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4+anti-PD-1",
    "PMID": "30753825",
    "Article Title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "SampleSize": "14",
    "ResponseSampleCount": "9",
    "NonresponseSampleCount": "5",
    "PretherapySampleCount": "11",
    "PosttherapySampleCount": "3"
  },
  {
    "DatasetID": "Melanoma-PRJEB23709_anti-CTLA-4+anti-PD-1_Male",
    "Dataset": "PRJEB23709",
    "CancerType": "Melanoma",
    "Therapy": "anti-CTLA-4+anti-PD-1",
    "PMID": "30753825",
    "Article Title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "SampleSize": "27",
    "ResponseSampleCount": "17",
    "NonresponseSampleCount": "10",
    "PretherapySampleCount": "21",
    "PosttherapySampleCount": "6"
  },
  {
    "DatasetID": "Melanoma-PRJEB23709_anti-PD-1",
    "Dataset": "PRJEB23709",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "30753825",
    "Article Title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "SampleSize": "50",
    "ResponseSampleCount": "23",
    "NonresponseSampleCount": "27",
    "PretherapySampleCount": "41",
    "PosttherapySampleCount": "9"
  },
  {
    "DatasetID": "Melanoma-PRJEB23709_anti-PD-1_Female",
    "Dataset": "PRJEB23709",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "30753825",
    "Article Title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "SampleSize": "17",
    "ResponseSampleCount": "10",
    "NonresponseSampleCount": "7",
    "PretherapySampleCount": "15",
    "PosttherapySampleCount": "2"
  },
  {
    "DatasetID": "Melanoma-PRJEB23709_anti-PD-1_Male",
    "Dataset": "PRJEB23709",
    "CancerType": "Melanoma",
    "Therapy": "anti-PD-1",
    "PMID": "30753825",
    "Article Title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "SampleSize": "33",
    "ResponseSampleCount": "13",
    "NonresponseSampleCount": "20",
    "PretherapySampleCount": "26",
    "PosttherapySampleCount": "7"
  },
  {
    "DatasetID": "nonsqNSCLC-GSE93157_anti-PD-1",
    "Dataset": "GSE93157",
    "CancerType": "Nonsquamous lung carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "22",
    "ResponseSampleCount": "6",
    "NonresponseSampleCount": "16",
    "PretherapySampleCount": "22",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "nonsqNSCLC-GSE93157_anti-PD-1_Female",
    "Dataset": "GSE93157",
    "CancerType": "Nonsquamous lung carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "7",
    "ResponseSampleCount": "0",
    "NonresponseSampleCount": "7",
    "PretherapySampleCount": "7",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "nonsqNSCLC-GSE93157_anti-PD-1_Male",
    "Dataset": "GSE93157",
    "CancerType": "Nonsquamous lung carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "28487385",
    "Article Title": "Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.",
    "SampleSize": "15",
    "ResponseSampleCount": "6",
    "NonresponseSampleCount": "9",
    "PretherapySampleCount": "15",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-Braun_2020_ALL",
    "Dataset": "Braun_2020",
    "CancerType": "Clear cell renal cell carcinoma",
    "Therapy": "ALL",
    "PMID": "32472114",
    "Article Title": "Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma",
    "SampleSize": "311",
    "ResponseSampleCount": "44",
    "NonresponseSampleCount": "237",
    "PretherapySampleCount": "311",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-Braun_2020_anti-PD-1",
    "Dataset": "Braun_2020",
    "CancerType": "Clear cell renal cell carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "32472114",
    "Article Title": "Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma",
    "SampleSize": "181",
    "ResponseSampleCount": "39",
    "NonresponseSampleCount": "133",
    "PretherapySampleCount": "181",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-Braun_2020_anti-PD-1_Female",
    "Dataset": "Braun_2020",
    "CancerType": "Clear cell renal cell carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "32472114",
    "Article Title": "Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma",
    "SampleSize": "44",
    "ResponseSampleCount": "13",
    "NonresponseSampleCount": "28",
    "PretherapySampleCount": "44",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-Braun_2020_anti-PD-1_Male",
    "Dataset": "Braun_2020",
    "CancerType": "Clear cell renal cell carcinoma",
    "Therapy": "anti-PD-1",
    "PMID": "32472114",
    "Article Title": "Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma",
    "SampleSize": "137",
    "ResponseSampleCount": "26",
    "NonresponseSampleCount": "105",
    "PretherapySampleCount": "137",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-Braun_2020_EVEROLIMUS",
    "Dataset": "Braun_2020",
    "CancerType": "Clear cell renal cell carcinoma",
    "Therapy": "EVEROLIMUS",
    "PMID": "32472114",
    "Article Title": "Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma",
    "SampleSize": "130",
    "ResponseSampleCount": "5",
    "NonresponseSampleCount": "104",
    "PretherapySampleCount": "130",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-Braun_2020_EVEROLIMUS_Female",
    "Dataset": "Braun_2020",
    "CancerType": "Clear cell renal cell carcinoma",
    "Therapy": "EVEROLIMUS",
    "PMID": "32472114",
    "Article Title": "Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma",
    "SampleSize": "38",
    "ResponseSampleCount": "0",
    "NonresponseSampleCount": "32",
    "PretherapySampleCount": "38",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-Braun_2020_EVEROLIMUS_Male",
    "Dataset": "Braun_2020",
    "CancerType": "Clear cell renal cell carcinoma",
    "Therapy": "EVEROLIMUS",
    "PMID": "32472114",
    "Article Title": "Interplay of Somatic Alterations and Immune Infiltration Modulates Response to PD-1 Blockade in Advanced Clear Cell Renal Cell Carcinoma",
    "SampleSize": "92",
    "ResponseSampleCount": "5",
    "NonresponseSampleCount": "72",
    "PretherapySampleCount": "92",
    "PosttherapySampleCount": "0"
  },
  {
    "DatasetID": "RCC-GSE67501_anti-PD-1",
    "Dataset": "GSE67501",
    "CancerType": "Renal cell carcinoma",
    "Therapy": "GSE67501",
    "PMID": "27491898",
    "Article Title": "Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma",
    "SampleSize": "11",
    "ResponseSampleCount": "4",
    "NonresponseSampleCount": "7",
    "PretherapySampleCount": "0",
    "PosttherapySampleCount": "11"
  },
  {
    "DatasetID": "STAD-PRJEB25780_anti-PD-1",
    "Dataset": "PRJEB25780",
    "CancerType": "Metastatic gastric cancer",
    "Therapy": "anti-PD-1",
    "PMID": "30013197",
    "Article Title": "Comprehensive Molecular Characterization of Clinical Responses to PD-1 Inhibition in Metastatic Gastric Cancer",
    "SampleSize": "78",
    "ResponseSampleCount": "21",
    "NonresponseSampleCount": "57",
    "PretherapySampleCount": "0",
    "PosttherapySampleCount": "78"
  }
]
